AI Science Tracker

Claude in biology labs: Biomni, MozzareLLM, and others

Anthropic · 15 Jan 2026 · biology

Discovery

Anthropic

Claude in biology labs: Biomni, MozzareLLM, and others

Anthropic describes three cases: Biomni (Stanford) completed a GWAS analysis in 20 minutes in an initial trial and suggested new transcription factors in embryonic development; MozzareLLM (MIT and Whitehead) interprets gene clusters from CRISPR screens; a third lab is still testing. This is an Anthropic account without independent evaluation; some figures are estimates.

Technology: Claude (Biomni, MozzareLLM)

Family Claude: profile · models page

Publication: Announcement only · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Announcement only
  • Test type: retrospective or benchmark
  • Tested: Biomni's case studies (GWAS analysis, cloning design blind-evaluated against a postdoc, embryonic-tissue cell analysis) were checked by the Biomni team, citing a bioRxiv preprint; MozzareLLM was assessed qualitatively by its lab, with no quantitative benchmark.
  • Still unknown: The article says the validation is not independent, some figures are estimates (such as the three-week human comparison), and Biomni cannot yet do everything out of the box.
  • AI role: A Claude-powered agent (Biomni) analysed GWAS and embryonic cell data and suggested transcription factors; a Claude-powered system (MozzareLLM) interprets gene clusters from CRISPR screens.

Evidence sources: https://www.anthropic.com/news/accelerating-scientific-research

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.